MindWalk Secures First LensAI Deal as Q3 Revenue Rises 52% to CAD 4.2M
SDGR•MindWalk Holdings reported Q3 revenue of CAD 4.2 million, up 52% with U.S. sales doubling, and secured its first LensAI platform contract with an enterprise client. Its HYFT® Technology powers ReefIQ and LensAI with a curated biological context layer covering 660 million patterns to curb AI hallucinations in drug discovery.
1. Q3 Financial Performance
MindWalk reported CAD 4.2 million in revenue for the quarter ended January 31, 2026, marking a 52% year-over-year increase. Growth was driven by a doubling of U.S. sales, reflecting accelerating adoption of its AI-enabled drug discovery tools.
2. HYFT® Technology and Products
The company’s proprietary HYFT® Technology serves as a biological context layer, integrating 660 million curated patterns to support AI reasoning. On this foundation, MindWalk markets ReefIQ™, which organizes fragmented discovery data, and LensAI™, its reasoning and agentic workflow platform.
3. Enterprise Contract and Growth Strategy
MindWalk secured its first annual LensAI platform contract with a leading enterprise client, establishing a recurring revenue stream it plans to scale. Management views this deal as validation of its strategy to prioritize biological data integrity over model size in AI-driven drug discovery.
